Abstract
A 76-year-old woman had recurrent urosepsis due to extended-spectrum beta -lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Drug Resistance, Bacterial*
-
Escherichia coli / drug effects*
-
Escherichia coli / enzymology
-
Escherichia coli / genetics
-
Escherichia coli Infections / drug therapy*
-
Escherichia coli Infections / microbiology*
-
Female
-
Humans
-
Imipenem / administration & dosage
-
Imipenem / pharmacology*
-
Imipenem / therapeutic use
-
Meropenem
-
Microbial Sensitivity Tests
-
Thienamycins / administration & dosage
-
Thienamycins / therapeutic use
-
Urinary Tract Infections / drug therapy
-
Urinary Tract Infections / microbiology
Substances
-
Anti-Bacterial Agents
-
Thienamycins
-
Imipenem
-
Meropenem